0001209191-18-004062.txt : 20180117
0001209191-18-004062.hdr.sgml : 20180117
20180117175830
ACCESSION NUMBER: 0001209191-18-004062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180112
FILED AS OF DATE: 20180117
DATE AS OF CHANGE: 20180117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kennedy Joseph T
CENTRAL INDEX KEY: 0001408920
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21392
FILM NUMBER: 18532417
MAIL ADDRESS:
STREET 1: C/O TRANSCEPT PHARMACEUTICALS, INC.
STREET 2: 1003 W. CUTTING BLVD., SUITE 110
CITY: POINT RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMARIN CORP PLC\UK
CENTRAL INDEX KEY: 0000897448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL,
STREET 2: SHELBOURNE ROAD, BALLSBRIDGE
CITY: DUBLIN
STATE: L2
ZIP: 00000
BUSINESS PHONE: 353 1 6699 020
MAIL ADDRESS:
STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL,
STREET 2: SHELBOURNE ROAD, BALLSBRIDGE
CITY: DUBLIN
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC
DATE OF NAME CHANGE: 20000201
FORMER COMPANY:
FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC
DATE OF NAME CHANGE: 19930322
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-12
0
0000897448
AMARIN CORP PLC\UK
AMRN
0001408920
Kennedy Joseph T
C/O AMARIN PHARMA, INC.
1430 ROUTE 206
BEDMINSTER
NJ
07921
0
1
0
0
General Counsel
Ordinary Shares
2018-01-12
4
S
0
9587
4.29
D
41519
D
Ordinary Shares
2018-01-16
4
S
0
10000
4.13
D
31519
D
Ordinary Shares
2018-01-17
4
S
0
31519
4.03
D
0
D
Sales made pursuant to a 10b5-1 trading plan dated December 9, 2016.
The Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.27 to $4.30, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Ordinary Shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.315, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Ordinary Shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.975 to $4.12, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Ordinary Shares sold at each separate price
Please see the section titled "Remarks" below for additional information.
As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 3,384,394 Ordinary Shares of the Issuer in the form of stock options and Restricted Stock Units granted under the Amarin Corporation plc 2002 Stock Option Plan and the Amarin Corporation plc 2011 Stock Incentive Plan.
/s/ Joseph T. Kennedy
2018-01-17